Asembia

Health-system specialty pharmacies leverage EHR insights to enhance real-world evidence, improve access, and streamline prior authorizations.

Experts dismantled the assumption that direct-to-patient is a universal affordability solution, offering manufacturers a practical framework for deciding which model is actually right.

Experts at AXS26 laid out why advanced therapies are underutilized and what payers, providers, and manufacturers must do together to change that.

Advanced therapies are pressuring reimbursement and necessitating real-world durability data and new payment models, said Fran Gregory, PharmD.

Specialty pharmacies play a critical role in connecting patients with assistance programs to combat growing financial complexities.

Pharmacy innovation—from automation to cell and gene therapy—has moved from future promise to present reality, says Cencora's Ryan Telford, PharmD.

At AXS26, leaders shared the hard-won organizational, strategic, and operational lessons from rounds 1, 2, and 3 of the Medicare Drug Price Negotiation Program.

Experts examine what is working in production, where the guardrails are being tested, and why the most transformative chapter of AI in health care hasn’t started yet.

As pricing reforms like Most Favored Nation reshape global drug launches, patients may ultimately pay the highest price, said Dee Chaudhary of Clarivate.

Drug pricing transparency and easy discounts cut abandoned prescriptions, as federal policies put pressure on pharma, says Laura Jensen of GoodRx.

The future of specialty pharmacy is not automation alone, but technology designed to assist patients through personalized support.

The entire commercial logic of the pharmaceutical industry’s patient engagement model is built for a moment that no longer exists, according to Chris Moose.

Policy and market access experts break down the compounding forces reshaping drug pricing, PBM regulation, and manufacturer strategy heading into the 2026 midterms.

Fran Gregory, PharmD, MBA, explains why community providers can't go it alone—and how specialty pharmacy is stepping in to carry the load.

A new industry report underscores the momentum—and the work ahead—as gene-, cell-, and tissue-based treatments move from academic health systems into community care.

AI revolutionizes pharmacy by automating workloads, enhancing patient care, and navigating drug pricing challenges amid evolving federal policies.

Systemic barriers beyond just the price of drugs can impact health care costs, emphasizing the need for comprehensive affordability solutions, explained H. John Beardsley, MBA, of CoverMyMeds, and Fauzea Hussain, MPH, of McKesson.

Medicare Part B drug negotiations in 2028 pose challenges for providers, requiring new payment systems and strategies to ensure patient access, explained H. John Beardsley, MBA, of CoverMyMeds, and Fauzea Hussain, MPH, of McKesson.

Drug companies and specialty distributors navigate challenges like profitability, supply chain volatility, regulatory complexities, and market pressures to build successful partnerships, said Natalie Bedford of McKesson.

To safely and successfully use artificial intelligence (AI) tools in the pharmacy, credentialing bodies and professional associations will need to validate these tools for the individual pharmacist, said Harry Travis of The Travis Group.

Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.

Innovative financing and reimbursement models can improve access to cell and gene therapies, addressing cost barriers and improving patient outcomes, said Joe DePinto, MBA, of McKesson.

Specialty distributors can help navigate complex health care regulations, ensuring compliance and adapting to changes in the landscape, said Natalie Bedford of McKesson.

Joe DePinto, MBA, of McKesson; Kathi Henson, MBA, of Orsini; and Natalie Bedford of McKesson discuss how Asembia's AXS25 Specialty Summit fosters collaboration among industry leaders, exploring technology trends to enhance specialty pharmacy and patient care delivery.

Experts champion medically integrated care and oncology optimized distribution models as vital strategies to improve outcomes, streamline access, and reduce costs for patients.

Experts urge for technology-driven, collaborative solutions as patients shoulder a growing burden of prescription costs.

Improving health equity is part of the core of quality improvement and requires data collection and community engagement strategies for underserved populations, said Shawn Griffin, MD, president and CEO of URAC.

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Strategic relationships and feedback can enhance specialty pharmacy operations, said Natalie Bedford, senior vice president of US pharmaceutical distribution services at McKesson.

Balancing technology and patient care can enhance communication and data collection, improving adherence and outcomes in specialty pharmacy, said Kathi Henson, MBA, of Orsini.